Home

HCW Biologics Inc. - Common Stock (HCWB)

0.2699
-0.0049 (-1.78%)

Hcw Biologics Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer and immune-related diseases

The company's pipeline includes a range of biologic products that harness the body's immune system to target and destroy cancer cells, aiming to improve patient outcomes and enhance the quality of life for those affected by such conditions. Through advanced research and development, Hcw Biologics is committed to addressing significant medical needs in the oncology space and advancing personalized medicine.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close0.2748
Open0.2620
Bid0.2610
Ask0.2699
Day's Range0.2620 - 0.2699
52 Week Range0.2103 - 2.520
Volume6,928
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume243,848

News & Press Releases

12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 23, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 20, 2024
Why Keysight Technologies Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · November 20, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 19, 2024
HCWB Stock Earnings: HCW Biologics Reported Results for Q2 2024investorplace.com
HCW Biologics just reported results for the second quarter of 2024.
Via InvestorPlace · August 14, 2024
HCWB Stock Earnings: HCW Biologics Reported Results for Q1 2024investorplace.com
HCW Biologics just reported results for the first quarter of 2024.
Via InvestorPlace · May 15, 2024
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · November 19, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 18, 2024
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!
Investors are turning their attention to a lineup of Nasdaq-listed companies making waves in their respective industries.
Via AB Newswire · November 18, 2024
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In Novembermarkets/com
Via Benzinga · November 18, 2024
Why Is Penny Stock HCW Biologics Surging On Monday?benzinga.com
HCW Biologics' stock rises as it partners with WY Biotech in an exclusive global license deal, securing $7 milion upfront and future potential milestone payments.
Via Benzinga · November 18, 2024
Dow Falls 100 Points; Brady Posts Upbeat Resultsmarkets/com
Via Benzinga · November 18, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 17, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · October 16, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · October 15, 2024
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga.com
Via Benzinga · October 4, 2024
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · September 30, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · April 12, 2024
HCWB Stock Earnings: HCW Biologics Misses EPS, Misses Revenue for Q4 2023investorplace.com
HCWB stock results show that HCW Biologics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via InvestorPlace · April 1, 2024
Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionbenzinga.com
Shares of Anavex Life Sciences Corp. (NASDAQAVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results.
Via Benzinga · November 27, 2023
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
Showed HCW9218 clinical safety and tumor response endpointsfor 15 patients with heavily pretreated advanced solid tumors
By HCW Biologics, Inc · Via GlobeNewswire · November 8, 2023
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
HCW9218 is the lead product candidate of HCW Biologics Inc.
By HCW Biologics, Inc · Via GlobeNewswire · November 1, 2023
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · September 14, 2023
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months
By HCW Biologics, Inc · Via GlobeNewswire · September 6, 2023
Nerdy And 3 Other Stocks Under $4 Insiders Are Aggressively Buyingbenzinga.com
The Dow Jones closed higher by around 90 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · June 8, 2023